FDA rejects Aldeyra’s eye cancer injection, citing lack of well-controlled studies FDA/Regulatory, R&D Wednesday, the FDA denied Aldeyra Therapeutics’ application for ADX-2191 (methotrexate injection, USP), which the Massachusetts biotech was proposing to treat the rare eye cancer primary vitreoretinal lymphoma. Read more June 22, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2023/06/Biospaceeye6-22-2023.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-06-22 10:08:102023-06-22 10:08:10FDA rejects Aldeyra’s eye cancer injection, citing lack of well-controlled studies
